Reply to "Risperidone-induced obsessive-compulsive symptoms: serotonin-dopamine imbalance?".
Alevizos
Basil
B
Lykouras
Lefteris
L
Zervas
Iannis M
IM
Christodoulou
George N
GN
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism*; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008134:Long-Term Care; D009771:Obsessive-Compulsive Disorder / Q000139:chemically induced*; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012701:Serotonin / Q000378:metabolism*; D058830:Serotonin 5-HT2 Receptor Antagonists
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D012701:Serotonin; D018967:Risperidone; D004298:Dopamine